Skip to content

Precigen PGEN Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Arrowhead Research logo
Arrowhead ResearchARWR
PVL
Palvella TherapeuticsPVLA
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's operating lease right-of-use assets in other assets?
Precigen (PGEN) reported operating lease right-of-use assets in other assets of $4.37M in Q1 2026.
How has Precigen's operating lease right-of-use assets in other assets changed year-over-year?
Precigen's operating lease right-of-use assets in other assets decreased by 13.8% year-over-year, from $5.07M to $4.37M.
What is the long-term trend for Precigen's operating lease right-of-use assets in other assets?
Over 5 years (2020 to 2025), Precigen's operating lease right-of-use assets in other assets has grown at a -12.9% compound annual growth rate (CAGR), from $9.35M to $4.68M.